AlphaCentric Advisors LLC bought a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 80,000 shares of the company's stock, valued at approximately $1,138,000.
A number of other institutional investors have also recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC purchased a new position in shares of Takeda Pharmaceutical in the 1st quarter worth $108,000. Sequoia Financial Advisors LLC increased its position in shares of Takeda Pharmaceutical by 10.7% during the 1st quarter. Sequoia Financial Advisors LLC now owns 22,396 shares of the company's stock valued at $311,000 after purchasing an additional 2,159 shares during the last quarter. Callan Capital LLC lifted its stake in shares of Takeda Pharmaceutical by 89.3% in the 1st quarter. Callan Capital LLC now owns 25,461 shares of the company's stock worth $354,000 after purchasing an additional 12,010 shares during the period. Lester Murray Antman dba SimplyRich bought a new stake in Takeda Pharmaceutical during the first quarter valued at approximately $351,000. Finally, Gallacher Capital Management LLC increased its holdings in Takeda Pharmaceutical by 6.1% during the first quarter. Gallacher Capital Management LLC now owns 16,229 shares of the company's stock valued at $225,000 after buying an additional 927 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.
Takeda Pharmaceutical Stock Performance
NYSE:TAK traded up $0.19 during mid-day trading on Tuesday, hitting $14.24. 771,717 shares of the company traded hands, compared to its average volume of 1,839,607. The firm has a market cap of $45.31 billion, a price-to-earnings ratio of 24.52, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08. The stock's fifty day moving average price is $14.46 and its 200-day moving average price is $13.80. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64.
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
